Overview: Autoimmune Cerebellar Ataxia Antibody Mix TestIntroduction: The Autoimmune Cerebellar Ataxia Antibody Mix Test tests for a mix of antibodies causing cerebellar ataxia, leading to balance and coordination problems, often linked to autoimmune or paraneoplastic conditions, aiding in diagnosis. Affecting 1 in 100,000 people annually, this condition poses diagnostic challenges due to its diverse causes. Following 2023 American Neurological Association (ANA) guidelines, it uses immunofluorescence for high specificity, supporting immunology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: ACAA Mix Antibody Test, Cerebellar Ataxia Panel.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Antibody testing for ataxia began in the 1990s with research by Dalmau, who identified multiple autoantibodies. Immunofluorescence advancements in the 2010s by Inova Diagnostics improved detection, surpassing earlier Western blot methods.
Purpose: Detects a mix of ataxia antibodies to diagnose autoimmune or paraneoplastic cerebellar ataxia, guides immunosuppressive therapy, and evaluates patients with balance issues, aiming to address underlying causes.
Test Parameters: Autoimmune ataxia antibody levels
Pretest Condition: No special preparation required to reflect natural antibody levels. Collect serum or CSF. Report history of balance issues.
Specimen: Serum (SST, 2-5 mL), CSF (sterile container, 1-2 mL); 2 mL serum in SST or 1 mL CSF in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document balance or coordination problems. Include current medications or cancer history.
Consent: Written consent required, detailing the test's purpose, ataxia risks (e.g., disability), and sample collection risks.
Procedural Considerations: Uses immunofluorescence to detect antibody mix, requiring labs with fluorescent microscopes. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive antibody mix confirms ataxia, guiding therapy. Early treatment might prevent progression, while untreated cases lead to disability. Normal levels may require MRI.
Specialist Consultation: Consult a neurologist for interpretation.
Additional Supporting Tests: MRI, anti-Yo test, or PET-CT to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with imaging needed. False negatives possible in early stages.
References: ANA Guidelines, 2023; Neurology, Dalmau J, 2022.
